Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.97Last Year’s EPS
2.54Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging progress in strategic growth areas (diagnostics rebound, ddPCR/QX700 momentum, earlier-than-expected accretion from the Stilla acquisition, robust free cash flow and a strong balance sheet) alongside material execution and margin challenges (Q4 gross margin pressure, one-time write-offs, GAAP impairment charges, Life Science softness and near-term process chromatography headwinds). Management provided conservative but constructive 2026 guidance and detailed operational actions to address supply chain and cost issues. Overall, positives around cash generation, product momentum and disciplined M&A/capital allocation are balanced by near-term profitability and execution risks.Company Guidance
Revenue Growth in Q4 and Full Year Stability
Q4 2025 net sales were $693 million, up 3.9% reported and 1.7% currency-neutral versus Q4 2024. Full year 2025 net sales were $2.583 billion, up 0.7% reported and essentially flat on a currency-neutral basis versus 2024.
Clinical Diagnostics Returned to Growth
Q4 Clinical Diagnostics sales were ~$425 million, an 8.4% increase reported and 5.6% currency-neutral versus Q4 2024, driven by quality control and blood typing products; full year Diagnostics sales grew 1.6% reported (0.8% currency-neutral).
ddPCR Momentum and Successful QX700 Launch
ddPCR portfolio posted mid-single-digit year-over-year growth in Q4; QX700 instrument sales meaningfully accelerated in Q4 and helped expand the order funnel entering 2026. Management expects ddPCR to be a core long-term growth pillar and guides ddPCR growth at mid-single digits for 2026.
Stilla Acquisition Accreting Sooner Than Expected
Management indicated the Stilla acquisition will be accretive by mid-2026 — 6 to 12 months earlier than initially expected — and Stilla contributed mid-single-digit millions of revenue in Q4.
Strong Cash Generation and Free Cash Flow Improvement
Q4 2025 net cash from operations was $165 million (vs. $124M prior year); full year operating cash flow improved to $532 million (vs. $455M). Free cash flow for 2025 was ~$375 million (vs. $290M), with a free cash flow to non-GAAP net income conversion of 138%.
Balance Sheet and Capital Allocation
Total cash and short-term investments of $1.541 billion at year-end; repurchased 1.2 million shares in 2025 for ~$296 million and 1.9 million shares total since Q1 2024 (~$494M), reducing share count by ~6.6%. Company has ~$285 million remaining under current buyback authorization.
Process Chromatography Full-Year Strength (Management Commentary)
Management stated the process chromatography business delivered over 20% growth in 2025 (noting this business can be lumpy and concentrated on select commercial therapeutics and vaccines).
Clear and Conservative 2026 Guidance
Company guided to 2026 currency-neutral revenue growth of 0.5%–1.5% (Q1 down low-single digits with sequential improvement), full-year non-GAAP gross margin 54.0%–54.5%, non-GAAP operating margin 12.0%–12.5%, and free cash flow $375M–$395M.
BIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $292.42 | $256.56 | -12.26% |
Oct 29, 2025 | $319.47 | $304.61 | -4.65% |
Jul 31, 2025 | $241.95 | $284.60 | +17.63% |
May 01, 2025 | $240.43 | $236.34 | -1.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bio-Rad Laboratories (BIO) report earnings?
Bio-Rad Laboratories (BIO) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Bio-Rad Laboratories (BIO) earnings time?
Bio-Rad Laboratories (BIO) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIO EPS forecast?
BIO EPS forecast for the fiscal quarter 2026 (Q1) is 1.97.